Treats hypertension. ANDA 203978, held by Inforlife. Nicardipine Hydrochloride.
As of Nov 22, 2026, ANDA 203978 (Nicardipine Hydrochloride In 0.86% Sodium Chloride, Nicardipine Hydrochloride In 0.83% Sodium Chloride), held by Inforlife, was first approved by FDA on Apr 17, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2024 | Original application | Approved |
| Nicardipine Hydrochloride In 0.86% Sodium Chloride20MG/200ML (0.1MG/ML) · injectable;intravenous | Nicardipine Hydrochloride | Rx |
| Nicardipine Hydrochloride In 0.83% Sodium Chloride40MG/200ML (0.2MG/ML) · injectable;intravenous | Nicardipine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters